Totally agree Silverchair. The FDA has de-risked CUV as a business, and with the Australian TGA approval the lumpiness in revenue should improve. With a large amount of cash in the bank, they can move into the US and still have cash for developing new products with their IP Low risk to reward ratio for those who are patient.
Totally agree Silverchair. The FDA has de-risked CUV as a...
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.73 |
Change
0.140(0.96%) |
Mkt cap ! $725.6M | |||
| Open | High | Low | Value | Volume |
| $14.76 | $14.78 | $14.46 | $480.6K | 32.89K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 32 | $14.73 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.75 | 114 | 8 |
View Market Depth
| Last trade - 11.25am 31/07/2024 (20 minute delay) ? |
| CUV (ASX) Chart |